Pre-made Suptavumab benchmark antibody ( Whole mAb, anti-RSV gpF therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Suptavumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Suptavumab (INN; development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-535-1mg	1mg	3090
GMP-Bios-ab-535-10mg	10mg	Inquiry
GMP-Bios-ab-535-100mg	100mg	Inquiry
GMP-Bios-ab-535-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Suptavumab biosimilar, Whole Mab: Anti-RSV gpF therapeutic antibody
INN Name	Suptavumab
Target	RSV gpF
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Regeneron Pharmaceuticals
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Respiratory syncytial virus infections
Development Tech	VelocImmune Mouse;VelociGene